Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 44(6): 1604-8, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10817716

ABSTRACT

Gemifloxacin (known as SB-265805 or LB-20304) is a potent, novel fluoroquinolone compound with a broad spectrum of antibacterial activity. The pharmacokinetics and tolerability of oral gemifloxacin were characterized in healthy male volunteers after a single dose of 20, 40, 80, 160, 320, 600, or 800 mg. Multiple serum and urine samples were collected and analyzed for gemifloxacin using high-performance liquid chromatography with fluorescence detection. Safety assessments included vital signs, 12-lead electrocardiogram readings, hematology, clinical chemistry, urinalysis, and adverse-experience monitoring. Gemifloxacin was rapidly absorbed after all doses. Maximum concentrations of gemifloxacin in serum (C(max)) were achieved approximately 1 h after dosing, after which concentrations in serum declined in a biexponential manner. Values of C(max) and the area under the concentration-time curve in serum from 0 h to infinity (serum AUC(0-infinity)) increased linearly with dose. Serum AUC(0-infinity) values (mean +/- standard deviation) were 0.65+/-0.01, 1.28+/-0.22, 2.54+/-0.31, 5.48+/-1.24, 9.82+/-2.70, 24.4+/-7.1, and 31.4+/-7.6 microg. h/ml following 20-, 40-, 80-, 160-, 320-, 600-, and 800-mg doses, respectively. The terminal phase elimination half-life was independent of dose, with an overall mean of 7.4+/-2.0 h. The profiles indicated that the pharmacokinetic profile is suitable for a once-daily dosing regimen. Approximately 25 to 40% of the administered dose was excreted unchanged in the urine, and renal clearance (ca. 150 ml/min) was independent of dose. There were no significant changes in clinical chemistry, hematology, or urinalysis parameters, vital signs, or 12-lead electrocardiogram readings in subjects, irrespective of dose. The results of these studies support the further investigation of once-daily administration of gemifloxacin.


Subject(s)
Anti-Infective Agents/administration & dosage , Anti-Infective Agents/pharmacokinetics , Fluoroquinolones , Naphthyridines/administration & dosage , Naphthyridines/pharmacokinetics , Administration, Oral , Adult , Anti-Infective Agents/adverse effects , Female , Gemifloxacin , Humans , Male , Naphthyridines/adverse effects , Pregnancy
2.
Biochem Pharmacol ; 54(1): 97-101, 1997 Jul 01.
Article in English | MEDLINE | ID: mdl-9296355

ABSTRACT

Brazilin increased [3H]2-deoxyglucose uptake in isolated rat epididymal adipocytes. The fact that calcium may be required for the stimulatory effects of insulin on glucose transport suggests that brazilin might also require calcium for its glucose transport-stimulating action. Changes in the concentration of extracellular calcium had no significant effect on brazilin-induced glucose transport. Nifedipine and verapamil decreased brazilin-induced glucose transport, and quin2-AM abolished the effect of brazilin on glucose transport. A23187, however, showed no effect on brazilin action. 45Ca2+ uptake into adipocytes was not influenced by brazilin treatment, and trifluoperazine significantly inhibited the effect of brazilin on glucose transport. These data suggest that calmodulin and the maintenance of the intracellular calcium concentration, rather than an increase in it, may be essential for the stimulatory action of brazilin on glucose transport.


Subject(s)
Adipocytes/drug effects , Benzopyrans/pharmacology , Calcium/pharmacology , Glucose/metabolism , Hypoglycemic Agents/pharmacology , Adipocytes/metabolism , Animals , Benzopyrans/antagonists & inhibitors , Biological Transport/drug effects , Calcimycin/pharmacology , Calcium Channel Blockers/pharmacology , Calmodulin/metabolism , Cell Membrane/metabolism , Dose-Response Relationship, Drug , Epididymis/metabolism , Insulin Antagonists/pharmacology , Male , Nifedipine/pharmacology , Rats , Rats, Sprague-Dawley , Trifluoperazine/pharmacology , Verapamil/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...